Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Titel:
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Auteur:
Ferreri, Andrés J M Cwynarski, Kate Pulczynski, Elisa Ponzoni, Maurilio Deckert, Martina Politi, Letterio S Torri, Valter Fox, Christopher P Rosée, Paul La Schorb, Elisabeth Ambrosetti, Achille Roth, Alexander Hemmaway, Claire Ferrari, Angela Linton, Kim M Rudà, Roberta Binder, Mascha Pukrop, Tobias Balzarotti, Monica Fabbri, Alberto Johnson, Peter Gørløv, Jette Sønderskov Hess, Georg Panse, Jens Pisani, Francesco Tucci, Alessandra Stilgenbauer, Stephan Hertenstein, Bernd Keller, Ulrich Krause, Stefan W Levis, Alessandro Schmoll, Hans J Cavalli, Franco Finke, Jürgen Reni, Michele Zucca, Emanuele Illerhaus, Gerald